CSI Market
Sign In | Register

Adaptimmune Therapeutics Plc (ADAP) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ADAP Annual Cash Flow →
The table below presents a historical view of Adaptimmune Therapeutics Plc's cash flow activity, supporting analysis of liquidity trends over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2025)
6 Months 		(Mar 31 2025) (Dec 31 2024) (Sep 30 2024) (Jun 30 2024)
Operating Activities
Income-30.34
Depreciation & amortization4.62
Amortization of Other Assets0.36
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Long-Lived Assets Held-for-use0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-4.04
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation1.32
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), Unrealized-0.89
Increase Decrease In Current Assets-9.16
Increase Decrease In Noncurrent Assets-
Debt Securities Available For Sale Realized Loss-
Amortization Accretion Of Marketable Securities-
Increase Decrease In Borrowings-
Increase In Borrowings And Other Non Current Liabilities0.78
Accretion Amortization On Available For Sale Debt Securities-0.51
Income taxes0.06
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Other Operating Liabilities-11.41
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital0.56
Other Noncash Expense0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-5.81
Discontinued operations0.00
Net Cash flow from Operating Activities-101.37
Investing Activities
Capital Expenditures-1.28
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities76.95
Payments to Acquire Marketable Securities-16.09
Real Estate Investments0.00
Maturity Of Short Term Bank Deposits-
Increase in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Proceeds from Sale of Other Assets, Investing Activities0.06
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities59.64
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings-25.45
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.79
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-23.67
Effect of exchange rate on cash flow-0.03
Discontinued operations0.00
Free Cash Flow-102.65
Total Cash Flow-65.43
4 historic quarters locked

Sign in to unlock the full Adaptimmune Therapeutics Plc cash flow history.

Sign In Create Free Account

About Adaptimmune Therapeutics Plc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001558370-25-011307

Figures are derived from filed reports and may be restated. Historical data is subject to revision.